UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

For the Month of December 2014

001-36203
(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☑ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

This Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant's Registration Statements on Form F-3 (File Nos.. 333-195124 and 333-199033), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On December 1, 2014, Can-Fite BioPharma Ltd. issued a press release announcing its financial results for the nine months ended September 30, 2014 and a press release announcing US researchers published scientific findings that are a potential breakthrough for the prevention of neuropathic pain by CF101. A copy of these press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

Exhibit Index

Exhibit No.	Description
99.1	Press Release, dated December 1, 2014
99.2	Press Release, dated December 1, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Can-Fite BioPharma Ltd.

Date December 1, 2014

By: /s/ Motti Farbstein
Motti Farbstein
Chief Operating and Financial Officer

Exhibit 99.1

Can-Fite Reports Financial Results for Nine Months Ended September 30, 2014

PETACH TIKVA, Israel, December 1, 2014 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported financial results for the nine months ended September 30, 2014 and updates on its clinical programs.

Clinical and Corporate Highlights Include:

- ***CF101 – Data release from the Psoriasis Phase II/III study***

  Can-Fite has completed enrollment of over 300 patients at 17 clinical centers in the U.S., Europe, and Israel in its Phase II/III trial for the treatment of psoriasis. Top line results from the trial are expected in the first quarter of 2015. Can-Fite has already received positive interim data from the first 100 patients. In addition, Can-Fite is planning a Phase III trial for rheumatoid arthritis based on the positive data of its Phase II study. Data from the Phase II ongoing glaucoma study (aimed at 88 patients) is expected to be released in Q2/Q3 2015.

- ***CF102 – Initiation of global Phase II Liver Cancer study***

  A global Phase II trial for the treatment of patients with advanced hepatocellular carcinoma (HCC) will be initiated in the US, Europe and Israel. The study will entail 78 subjects and will investigate the efficacy and safety of CF102 given as a second line therapy in patients with Child Pugh B liver cirrhosis as compared to placebo.

- ***Development of a kit to analyze A3 adenosine receptor, utilized as a predictive biomarker***

  Can-Fite is developing a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR) predictive biomarker. The kit is designed to look at the A3 adenosine receptor expression levels prior to treatment with CF101 and predict patient's response to the drug. The U.S. Patent and Trademark Office had previously issued Can-Fite a patent for the utilization of A3AR as a biomarker to predict patients' response to CF101 in all autoimmune inflammatory indications.

Can-Fite CEO Dr. Pnina Fishman commented on the Company's recent achievements, stating, "In the third quarter, we moved forward with meaningful advances in each of our clinical programs and we are expecting to release data from our Phase II/III psoriasis trial during the first quarter of 2015. Subsequent to the end of the second quarter of 2014, Israel's Ministry of Health approved CF102 for Compassionate Use for a liver cancer patient who has already benefitted from the drug during clinical trials."

Research and development expenses for the nine months ended September 30, 2014 were NIS 12.44 million (U.S. $3.37 million) compared with NIS 10.19 million (U.S. $2.76 million) for the same period in 2013. Research and developments expenses for the first nine months of 2014 comprised primarily of expenses associated with the initiation of a planned Phase II study for liver cancer treatment with CF102, ongoing Phase II/II study for psoriasis treatment with CF101 as well as expenses for pre-clinical studies of CF102 and CF101.

General and administrative expenses were NIS 7.73 million (U.S. $2.09 million) for the nine months ended September 30, 2014 and NIS 9.61 million (U.S. $2.60 million) for the same period in 2013. The decrease is primarily due to a reduction in share based compensation expenses.

Financial income, net for the nine months ended September 30, 2014 aggregated NIS 3.28 million (U.S. $0.89 million) compared to financial income, net of NIS 0.21 million (U.S. $0.06 million) for the same period in 2013. The increase in financial income, net in the first nine months of 2014 was mainly due to a decrease in the fair value of the Company's warrants.

Can-Fite's loss for the first nine months ended September 30, 2014 was NIS 16.89 million (U.S. $4.57 million) compared to a loss of NIS 19.58 million (U.S. $5.30 million) for the same period in 2013. The decrease in net loss for the first nine months of 2014, was attributable to an increase in finance income, net.

As of September 30, 2014, Can-Fite had cash and cash equivalents of NIS 15.22 million (U.S. $4.12 million) as compared to NIS 20.77 million (U.S. $5.62 million) at December 31, 2013. The Company raised a net total of NIS 15.77 million (U.S. $4.27 million) during the first nine month of 2014 from Can-Fite's private placement during the three months ended March 31, 2014. The decrease in cash during that period was due to cash used to finance the operations exceeding the amount raised.

For the convenience of the reader, the reported NIS amounts have been translated into U.S. dollars, at the representative rate of exchange on September 30, 2014 (U.S. $ 1 = NIS 3.695).

The Company's consolidated financial results for the nine months ended September 30, 2014 are presented in accordance with International Financial Reporting Standards.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company's CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite's liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information please visit: www.can-fite.com

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	Convenience translation Into U.S. dollars		
	September 30, 2014	September 30, 2014	December 31, 2013
	Unaudited	Unaudited	Audited
	In thousands	NIS in thousands	
ASSETS			
CURRENT ASSETS:			
Cash and cash equivalents	4,118	15,215	20,767
Accounts receivable	688	2,544	2,161
Total current assets	4,806	17,759	22,928
NON-CURRENT ASSETS:			
Lease deposits	9	34	34
Property, plant and equipment, net	38	139	143
Total long-term assets	47	173	177
Total assets	4,853	17,932	23,105

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	Convenience translation Into U.S. dollars.		
	September 30, 2014	September 30, 2014	December 31, 2013
	Unaudited	Unaudited	Audited
	In thousands	NIS in thousands	
LIABILITIES AND SHAREHOLDERS' EQUITY			
CURRENT LIABILITIES:			
Trade payables	682	2,520	2,056
Other accounts payable	779	2,876	5,276
Warrants exercisable into shares (series 7)	-	-	119
Total current liabilities	1,461	5,396	7,451
NON-CURRENT LIABILITIES:			
Warrants exercisable into shares	374	1,383	-
Severance pay, net	36	131	129
Total long-term liabilities	410	1,514	129
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:			
Share capital	1,229	4,542	4,037
Share premium	75,731	279,825	267,946
Capital reserve from share-based payment transactions	4,385	16,203	15,761
Warrants exercisable into shares (series 9-12)	2,612	9,652	9,652
Treasury shares at cost	(982)	(3,628)	(3,628)
Accumulated other comprehensive loss	(149)	(549)	(151)
Accumulated deficit	(80,314)	(296,760)	(280,391)
Total equity attributable to equity holders of the Company	2,512	9,285	13,226
Non-controlling interests	470	1,737	2,299
Total shareholders' equity	2,982	11,022	15,525
Total liabilities and shareholders' equity	4,853	17,932	23,105

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Convenience translation into U.S. dollars	Nine months ended September 30,	
	Nine months ended September 30, 2014	2014	2013
	Unaudited		
	In thousands	NIS in thousands (except per share data)	
Research and development expenses	3,367	12,441	10,185
General and administrative expenses	2,092	7,729	9,605
Operating loss	5,459	20,170	19,790
Finance expenses	140	515	374
Finance income	(1,027)	(3,795)	(584)
Loss	4,572	16,890	19,580
Other comprehensive loss (income):			
Exchange differences of foreign operations	131	485	245
Total comprehensive loss	4,703	17,375	19,825
Loss attributable to:			
Equity holders of the Company	4,431	16,369	18,012
Non-controlling interests	141	521	1,568
	4,572	16,890	19,580
Total comprehensive loss attributable to:			
Equity holders of the Company	4,538	16,767	18,213
Non-controlling interests	165	608	1,612
	4,703	17,375	19,825
Net loss per share attributable to equity holders of the Company :			
Basic and diluted net loss per share	0.26	0.95	1.38

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

Exhibit 99.2

US Researchers Published Scientific Findings that are a Potential Breakthrough for Prevention of Neuropathic Pain by CF101

PETACH TIKVA, Israel, December 1, 2014 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported newly published scientific findings conducted by St. Louis University researchers, Daniela Salvemini and colleagues in collaboration with Dr. Jacobson from the National Institutes of Health (NIH), on the prevention of neuropathic pain by CF101, generically known as IB-MECA. According to the research, the latter binds with high affinity to the A3 adenosine receptor and via specific mechanistic pathways significantly reduces neuropathic pain in animal models. Can-Fite CEO Dr. Pnina Fishman commented on these findings, stating, "It is very interesting that our drugs have additional well-defined clinical application in the field of neuropathic pain which is an unmet need. The study indicates some compelling results that relate to our CF101 and CF102 drugs. Former studies from the same group also showed similar data utilizing CF102, known as Cl-IB-MECA. In addition, this group showed earlier that CF101 prevents chemotherapy-induced peripheral neuropathy in pre-clinical studies. We believe that the A3 adenosine platform technology that we have been developing over the past decade and the excellent safety profile of the drugs has the potential to yield a unique therapy for this patient population."

While Can-Fite holds an exclusive worldwide license from NIH for clinical development of IB-MECA and Cl-IB-MECA, these compounds may be used for basic research purposes in the lab.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company's CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite's liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information please visit: www.can-fite.com

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114